272 related articles for article (PubMed ID: 20132153)
1. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
Miner P; Delemos B; Xiang J; Lococo J; Ieni J
Aliment Pharmacol Ther; 2010 May; 31(9):991-1000. PubMed ID: 20132153
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Fass R; Delemos B; Nazareno L; Kao R; Xiang J; Lu Y
Aliment Pharmacol Ther; 2010 May; 31(9):950-60. PubMed ID: 20132154
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Warrington S; Baisley K; Lee D; Lomax K; Delemos B; Boyce M; Morocutti A
Aliment Pharmacol Ther; 2007 Feb; 25(4):511-7. PubMed ID: 17270007
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Morgan D; Pandolfino J; Katz PO; Goldstein JL; Barker PN; Illueca M
Aliment Pharmacol Ther; 2010 Jul; 32(2):200-8. PubMed ID: 20456300
[TBL] [Abstract][Full Text] [Related]
5. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
6. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
7. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
Castell D; Bagin R; Goldlust B; Major J; Hepburn B
Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Eggleston A; Katelaris PH; Nandurkar S; Thorpe P; Holtmann G;
Aliment Pharmacol Ther; 2009 May; 29(9):967-78. PubMed ID: 19210493
[TBL] [Abstract][Full Text] [Related]
11. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
Pehlivanov ND; Olyaee M; Sarosiek I; McCallum RW
Aliment Pharmacol Ther; 2003 Nov; 18(9):883-90. PubMed ID: 14616152
[TBL] [Abstract][Full Text] [Related]
12. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
Johnson D; Crawley JA; Hwang C; Brown K
Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
[TBL] [Abstract][Full Text] [Related]
14. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
[TBL] [Abstract][Full Text] [Related]
15. [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
Fan YH; Lü B; Zhan LX; Zhang L
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):475-7. PubMed ID: 17663823
[TBL] [Abstract][Full Text] [Related]
16. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
Armstrong D; James C; Camacho F; Chen Y; Horbay GL; Teixeira B; Husein-Bhabha FA
Aliment Pharmacol Ther; 2007 Jan; 25(2):185-96. PubMed ID: 17116123
[TBL] [Abstract][Full Text] [Related]
17. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Miner P; Orr W; Filippone J; Jokubaitis L; Sloan S
Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
[TBL] [Abstract][Full Text] [Related]
18. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
[TBL] [Abstract][Full Text] [Related]
19. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
